Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY OF INOTUZUMAB OZOGAMICIN IN CHINESE ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

NCT05687032 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05687032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05687032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY OF INOTUZUMAB OZOGAMICIN IN CHINESE ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
February 24, 2023
Completion date
November 6, 2025
Enrollment
44 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia